Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 4,244 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Menopause, Sleep Disturbance, Anxiety, Depression, Cognitive Function, Fatigue, Libido
Interventions: Radicle Revive Placebo Control Form 4.1, Radicle Revive Active Study Product 4.1 Usage; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease
Interventions: Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions: continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp; Device · Drug · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 40 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Brain Injuries, Brain Injuries, Traumatic, Brain Injury, Chronic
Interventions: Tolcapone 200 MG, Placebo; Drug · Other
Lead sponsor: Sheppard Pratt Health System; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Dry Eye
Interventions: Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose, Corticosteroid Eye Drop; Drug
Lead sponsor: Ocugen; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Hoffman Estates, Illinois • Yorkville, Illinois • Salt Lake City, Utah

Conditions: Photoaging, Wrinkle, Skin Laxity
Interventions: Fractional Ablative CO2 Laser, Facial Cleanser, Facial Moisturizer, Sunscreen, Basic Ointment; Procedure · Other
Lead sponsor: Revision Skincare; Industry
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Blue Ash, Ohio

Conditions: HIV Infections, Peripheral Nervous System Diseases, Pain
Interventions: Capsaicin Dermal Patch; Drug
Lead sponsor: NeurogesX; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Sarasota, Florida • Annandale, Virginia

Conditions: Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions: placebo, iv sildenafil; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 0 Days to 4 Days
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 20
States / cities: Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more

Conditions: Alzheimer Disease
Interventions: ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo; Biological · Drug
Lead sponsor: Alzamend Neuro, Inc.; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Doral, Florida

Conditions: Glioma
Interventions: AG-120, AG881; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Diabetes Mellitus, Type 2
Interventions: rosiglitazone/metformin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 49
States / cities: Anniston, Alabama • Chandler, Arizona • Phoenix, Arizona + 41 more

Conditions: Seasonal Allergic Rhinitis
Interventions: ACT-129968, Placebo, Cetirizine; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 12 Years to 76 Years
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more

Conditions: Metastatic Prostate Cancer
Interventions: AZD0754, AZD2287; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more

Conditions: Opiate Addiction
Interventions: Cannabidiol 400, Cannabidiol 800, Control; Drug
Lead sponsor: Hurd,Yasmin, Ph.D.; Individual
Eligibility: 21 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatocellular Carcinoma
Interventions: Durvalumab, Bevacizumab, Placebo, Transarterial Chemoembolization (TACE); Drug · Other · Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 24
States / cities: Costa Mesa, California • La Jolla, California • Orange, California + 19 more

Conditions: Pain, Nausea, Vomiting
Interventions: CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), Placebo; Drug
Lead sponsor: Charleston Laboratories, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Postoperative Pain, Inflammation, Osteoarthritis
Interventions: Dexamethasone 10 mg, Dexamethasone 20 mg, Standard multimodal pain management regimen, Placebo; Drug
Lead sponsor: Thomas L Bradbury; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tucker, Georgia

Conditions: Diabetes Mellitus, Type 2
Interventions: Alogliptin, Metformin, Alogliptin Placebo, Metformin Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 109
States / cities: Dothan, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 106 more

Conditions: HIV Infections
Interventions: Modified Directly Observed Therapy, Standard Care; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Panic Disorder
Interventions: placebo, alprazolam XR; Other · Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 18
States / cities: Hialeah, Florida • Jacksonville, Florida • North Miami, Florida + 15 more

Conditions: Joint Pain
Interventions: Joint Health Product, Placebo, Glucosamine / Chondroitin; Dietary Supplement
Lead sponsor: U.S. Nutraceuticals, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Sausalito, California

Conditions: Opioid Dependence, Opioid Use Disorder (OUD)
Interventions: VK4-116, Placebo; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Friedreich Ataxia
Interventions: Idebenone; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 9 Years to 17 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Covid19
Interventions: Telmisartan Oral Product, Placebo; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Honolulu, Hawaii

Search by objective public record fields.

Radicle Revive 24: A Study of Health and Wellness Products on Menopausal Health and Related Health Outcomes

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

A Trial Evaluating Effects of COMT Inhibition in Patients With Acquired Brain Injury

Dry Eye Disease Study With Brimonidine

Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation

Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics

Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis

Study of AZD0754 in Participants With Metastatic Prostate Cancer

Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain

Steroids in Total Knee Arthroplasty

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

Modified Directly Observed Therapy for Improving Antiretroviral Therapy Adherence in People With HIV

A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder

Study to Evaluate the Safety and Efficacy of a Proprietary "Joint Health" Dietary Supplement in Subjects With Joint and Connective Tissue Pain

VK4-116 Phase I Study With Food-Effect

Idebenone to Treat Friedreich's Ataxia

INvestigating TELmisartin Study